Osmetech acquired the Opti product line from Roche Diagnostics. Opti is the portable analysis technology for bloodgas and electrolytes measurement. This highly successful analyser has also taken the veterinary world by storm. IDEXX Laboratories Inc (IDXX) have entered into a ten year OEM agreement to provide the customised OPTI analysers to the veterinary field under the brand VetStat.

In September 2004 the company acquired the "OPTIgene" (Genedrive) product from MS this technology will enable OMH a strong entry point into the fastest growing market segment of DNA based diagnostics. A market that is growing at an annual rate of 20% and is currently worth $ 22 bln !

In the latest acquisition 1/7/05 Osmetech acquired Clinical Micro Sensors from Motorola PLC, OMH plans to utilise the eSensor technology coupled with OPTIgene to address the majority of existing and new tests in the genetic diagnostics market. 'CMS's diagnostic tests for cystic fibrosis and CYP450 are closest to commercial launch and OMH believes that these products have significant market potential.

Scroll & Click for Websites & Other LinksRT Mag Wall Street Reporter Interviews JW

Up Coming Events in 2006

CMS CYP450 product Launch!!!!!............................................. 2006

IDEXX critical care platform Launch!!!!!....................................2006/7....much more to follow

Click Here to Track Osmetech's Progress in the "Stocks That Could Double in 2006" Competition

Major holders table updated. UBS being the latest buyers

MajorShareHolders No. Shares(%) Gartmore 31,279,344(15.42) Schroder 27,966,506(13.79) UBS AG 25,346,239 (12.5) Universities S S LTD 8,900,000(4.39) Pershing Keen 5,870,773 (2.89) Roche 2,444,688 (1.21) EBMF Ltd 18,000,000(8.88) Total 119,807,550 (59.08)

Todays Breakout of the inverse head and shouldes give a short term price target of c 32p

Nice continuation of the breakout today.

looking good

Moving up again.

OMH - now Gartmore's second largest holding!

http://www.advfn.com/p.php?pid=nmona&cb=1165236703&symbol=gsm&article=0018245385

Nicely on track for the c32p price projection based on the highly accurate inverse head and shoulders formation.

Trading Statement due early 2007

Some big BUY's put through after hours.

Time Price Quantity Type Bid Offer Buy/Sell Total Buy Total Sell Total Unknown
07/12/06 17:06 27.027 500,000 B 25.0 28.0 Buy 856,911 748,631 380,000
07/12/06 16:34 27.0 500,000 O 25.0 28.0 Buy 1,431,911 748,631 380,000
07/12/06 16:34 27.0 500,000 O 25.0 28.0 Buy 1,931,911 748,631 380,000
07/12/06 17:11 26.92 425,000 O 25.0 28.0 Buy 2,356,911 748,631 380,000

<>

Are we expecting the results at the end of january bangers?

I should think around that time but there's the Trading Statement to look forward to first! And perhaps more BIG news in the mean time!?

Considering in July OMH were forecasting 'record sales performance
during the next six month period' i would expect this TS to be more than upbeat.

Would you expect the price to rise prior to the TS & results then?

So potentially we are looking at another 6 weeks of continues rises?

Yep, and no reason why it should stop then.

Some of the largest trades from this week.

Time Price Quantity Type Bid Offer Buy/Sell Total Buy Total Sell Total Unknown
08/12/06 16:39 27.88 710,000 T 27.25 28.0 2,326,622 436,644 55,000
07/12/06 17:06 27.027 500,000 B 25.0 28.0 Buy 856,911 748,631 380,000
07/12/06 16:34 27.0 500,000 O 25.0 28.0 Buy 1,431,911 748,631 380,000
07/12/06 16:34 27.0 500,000 O 25.0 28.0 Buy 1,931,911 748,631 380,000
08/12/06 09:03 26.92 425,000 L 0.0 0.0 ? 0 0 0
07/12/06 17:11 26.92 425,000 O 25.0 28.0 Buy 2,356,911 748,631 380,000
08/12/06 13:39 27.875 200,000 T 27.5 28.0 Buy 1,432,991 373,072 55,000
08/12/06 09:14 28.0 200,000 T 27.5 28.0 Buy 667,890 8,800 0

Quiet here, soooooo

The men in suits have been at Osmo HQ, due diligence seems to be buzz word.

The gossip is that there are "new investors" floating about. Some of the ex CMS die hards think they have seen it all before and are concerned they could be getting sold off and made redundant again. Time will tell

4 possible scenarios are
A deal for or fire sale of the OPTIgene technology to Idexx and the closure of the Boston office.
Another placing to fund further development / purchase of new technology.
A major deal to supply XT-8 equipment.
A major co taking a significant stake or complete buy out.

Take your pick.
I wonder how long it will be before any one notices this. he he


Anyone notice that OPTIGene, genesensor whatever has vanished from the product list?

Maybe even two, as it seems there has been a few big buyers competing for stock.

Looking very strong now.

The thread dimwits have gone quiet all of a sudden. Cant think why?

the price we are at now offered resistance in jan 06 and april 05, we really need some good news to get past 30p and hold there then upto 34p.

But can trend lines and past resistance areas be relied upon due to the increased number of shares since those times?? Either way not long to the trading statement early '07 and of course there's always the chance of something else BIG(!?) before then!?

MajorShareHolders No. Shares(%) Gartmore 31,279,344(15.42) Schroder 27,966,506(13.79) UBS AG 24,261,239(11.96) Universities S S LTD 8,900,000(4.39) Pershing Keen 5,870,773 (2.89) Roche 2,444,688 (1.21) EBMF Ltd 18,000,000(8.88) Total 118,722,550(58.54)

"Austin-based Luminex Corp. and Tm Bioscience Corporation today announced a definitive agreement for Luminex to acquire Tm Bioscience Corporation, a leader in the commercial genetic testing market."
Luminex to acquire molecular diagnostics company

(Thanks to Bucketfull on AFN)

Thanks to Bruce (AFN)

Citywire tip - just out!
http://www.citywire.co.uk/News/NewsArticle.aspx?VersionID=87844&NewsPage=2

The recent announcement by molecular diagnostics testing company Osmetech (OMH) regarding the sale of its Critical Care division to IDEXX has led to a surprising 11.5% fall in its share price to a current mid-price of 25p.

In all fairness the shares experienced an excellent run prior to the disposal, with a gain of almost 80% from its lows back in September.

The company revealed it had sold the Critical Care Division for $44.9 million (22.9 million), a 15-fold increase from its original purchase price back in 2003. The company also said the cash balance at the end of November was 7.98 million.

Should Osmetech obtain shareholder approval at its extraordinary general meeting on 9 January, then before any cash burn, the company should be sitting on more than 30 million in liquid reserves. And with a market capitalisation of 50 million, the enterprise value is just 20 million.

The company will now specialise solely in molecular diagnostics which it promotes as the fastest growing sector of the global diagnostics market.

Osmetech intends to use the sale proceeds to develop and commercialise its existing product pipeline, secure licensing agreements and explore acquisition targets in the molecular diagnostics field. It may even consider entering non-healthcare markets to leverage its intellectual property.

It is interesting to note that since the disposal, UBS increased its holding in Osmetech by 785,000 shares to 12.35% of the company. And the last trade reported on 18 December was for 785,000 shares at 30.5p, a trade I suspect that belongs to UBS. On that basis it appears that the smart money is prepared to pay top dollar for the stock.

Although a comparison with fellow diagnostic company Proteome Sciences (PRM) is a bit tenuous, the difference in sheer valuations is startling. As of its last set of results in September, Proteome had just 900,000 cash with a 2 million loan facility.

The company is capitalised at 80 million suggesting an enterprise value of 79 million, barring non-cash assets. Osmetechs is just 20 million come mid January. Given the companys prospects and its relative low valuation, long positions should be considered at market with a stop-loss based on a close below 21p.